Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease

Table 3 Comparative of maintenance of remission at 12 mo in patients with initial remission in both groups

	Infliximab original group	95%CI	CT-P13group	95%CI	P value	Rate Difference (95%CI)
Maintained basal remission at 12 mo	62/74 (83.7%)	74.7-92.9	54/74 (72.9%)	62.2-83.5	0.162	-0.037-0.253
Maintained basal remission at 12 mo CD	42/51 (82.3%)	70.9-93.8	37/53 (69.8%)	56.5-83.1	0.205	-0.056-0.307
Maintained basal remission at 12 mo UC	20/23 (87%)	66.4-97.2	17/21 (81.0%)	62.5-92.5	0.890	-0.203-0.23

CD: Crohn's disease; UC: Ulcerative colitis.